Retinal Ganglion Cell Complex Changes after Intravitreal Bevacizumab for Diabetic Macular Edema

Shaheer, Muhammad; Amjad, Arooj; Saleem, Zubair

doi:10.29271/jcpsp.2019.05.426

Cited by 4 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, one could hold the opinion that the possible in uence of anti-VEGF treatment on injured RGCs after an ischemic insult, which is currently under investigation with inconsistent data in the literature [24][25][26]. In our subgroup analysis based on the "dried retina" after anti-VEGF injections, the opposite area in the BRVO eyes and its corresponding area in fellow eyes had no difference suggesting the intravitreal injections had no effect on the ganglion cells loss.…”

Section: Discussionmentioning

confidence: 93%

Analysis of ganglion cell-inner plexiform layer thickness in retinal vein occlusion with resolved macular edema

Zheng

Yang

et al. 2022

Int Ophthalmol

View full text Add to dashboard Cite

Purpose. To analyze the retinal ganglion cell-inner plexiform layer (GCIPL) changes in retinal vein occlusion (RVO) eyes with resolved macular edema using optical coherence tomography. Methods.We compared the average and minimum GCIPL thickness in RVO eyes with fellow eyes and healthy controls including 40 unilateral RVO patients and 48 healthy subjects. The average GCIPL thickness in BRVO eyes was segmented into the affected and opposite area according to the site of lesion, comparing them with corresponding areas in fellow eyes. Furthermore, maximum central macular thickness (CMT), visual acuity (VA), and intravitreal injection times were recorded to investigate their relationship with the GCIPL thickness.Results.Despite no signi cant difference in CMT (P = 0.96), the average (P = 0.02 and P < 0.001, respectively) and minimum (both P < 0.001) GCIPL thickness were decreased in RVO eyes with resolved macular edema after treatment in comparison to fellow eyes and healthy eyes. Maximum CMT thickness was negatively correlated with the minimum GCIPL thickness (r = -0.47, P = 0.003). VA and average GCIPL thickness were associated (rs = -0.49, P = 0.002). In a subgroup analysis only included BRVO patients, the opposite area revealed no signi cant difference between two eyes (P = 0.91) although the affected area in BRVO eyes was decreased (P < 0.001).Conclusions. A decrease of GCIPL thickness in RVO was observed even after anatomic restoration and associated with VA prognosis. These GCIPL defects could be attributable to systemic risks and RVO itself, not anti-VEGF effects.

show abstract

Section: Discussionmentioning

confidence: 93%

Analysis of ganglion cell-inner plexiform layer thickness in retinal vein occlusion with resolved macular edema

Zheng

Yang

et al. 2022

Int Ophthalmol

View full text Add to dashboard Cite

show abstract

“…However, they have also been tested for neuroprotection in optic neuropathies, and they are in three different clinical trials for non-arteritic anterior ischemic optic neuropathy (ClinicalTrials.gov Identifier: NCT01330524, NCT00813059 and NCT00561834) in order to halt the progression of visual acuity and visual field loss due to the disease. The thickness of GCL increased after the treatment with bevacizumab in diabetic macular edema [295]. Moreover, levodopa-carbidopa is used to treat the symptoms of Parkinson's disease and it is in a phase 4 clinical trial for non-arteritic anterior ischemic optic neuropathy (ClinicalTrials.gov Identifier: NCT00432393).…”

Section: Clinical Trials Targeting Rgcs Neuroprotectionmentioning

confidence: 99%

Neuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Ahead

Boia

Ruzafa

Aires

et al. 2020

IJMS

View full text Add to dashboard Cite

The retinal ganglion cells (RGCs) are the output cells of the retina into the brain. In mammals, these cells are not able to regenerate their axons after optic nerve injury, leaving the patients with optic neuropathies with permanent visual loss. An effective RGCs-directed therapy could provide a beneficial effect to prevent the progression of the disease. Axonal injury leads to the functional loss of RGCs and subsequently induces neuronal death, and axonal regeneration would be essential to restore the neuronal connectivity, and to reestablish the function of the visual system. The manipulation of several intrinsic and extrinsic factors has been proposed in order to stimulate axonal regeneration and functional repairing of axonal connections in the visual pathway. However, there is a missing point in the process since, until now, there is no therapeutic strategy directed to promote axonal regeneration of RGCs as a therapeutic approach for optic neuropathies.

show abstract

“…5 Ganglion cell complex thickness (GCCT) plays a particularly important role in visual function and assessment of the visual field and has been analyzed in numerous in vitro and in vivo studies in humans and animals. [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] This study aimed to analyze the relationship between GCCT and vision compared with choroidal thickness (CT) and central retinal thickness (CRT) in relation to the outcomes of intravitreal aflibercept treatment for choroidal neovascular membranes secondary to AMD.…”

Section: Introductionmentioning

confidence: 99%

Relationship between ganglion cell complex thickness and vision in age-related macular degeneration treated with aflibercept

Buyukavsar

Sönmez

Sağdiç

et al. 2022

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose This study aimed to analyze the correlation between ganglion cell complex thickness (GCCT) and vision compared with the choroidal thickness (CT) and central retinal thickness (CRT) in relation to the outcomes of intravitreal aflibercept treatment for choroidal neovascular membranes secondary to age-related macular degeneration (AMD). Methods This was a prospective, observational study. Forty-three eyes of 38 patients with wet AMD received a monthly loading dose of 2 mg aflibercept by intravitreal injection (IVI) during the first 3 months and were then followed at regular monthly intervals for an average of 10 months by a pro re nata regimen. All patients were examined using spectral domain-optic coherence tomography (OCT) and enhanced depth imaging OCT. According to their response to IVI treatment in the third month, patients were divided into 2 groups, both functionally and anatomically. Results Three-month GCCT and optic disc retinal nerve fiber layer thickness (ODRNFLT) had the most correlation with the 10-month vision (p = 0.002, p = 0.02, respectively). While baseline GCCT was most correlated with the functional response, baseline CRT was most correlated with the anatomical response (p = 0.01, p = 0.004, respectively). Conclusions The results suggest that a reduction in 3-month GCCT indicates a good long-term vision outcome, while a reduction in 3-month ODRNFLT shows a poor long-term vision outcome. The literature suggests that this study is the first to demonstrate that baseline GCCT is more strongly correlated with the functional response than it is with CT and CRT. Hence, GCCT has a prognostic value for vision impairment.

show abstract

Retinal Ganglion Cell Complex Changes after Intravitreal Bevacizumab for Diabetic Macular Edema

Abstract: Objective: To measure the changes in ganglion cell complex as measured on optical coherence tomography (OCT) after intravitreal injection of bevacizumab (Avastin).

Cited by 4 publications

References 21 publications

Analysis of ganglion cell-inner plexiform layer thickness in retinal vein occlusion with resolved macular edema

Analysis of ganglion cell-inner plexiform layer thickness in retinal vein occlusion with resolved macular edema

Neuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Ahead

Relationship between ganglion cell complex thickness and vision in age-related macular degeneration treated with aflibercept

Contact Info

Product

Resources

About